Reconciliation via cumulative lifelong exposure
The argument
Short-term statin trials show about a fifth lower risk of major vascular events per mmol/L LDL reduction over roughly five years (linked claim), whereas Mendelian randomization estimates roughly a threefold greater reduction per mmol/L (linked claim). Because the per-unit benefit grows with duration of exposure (linked claim) and genetic variants proxy lifelong lower LDL while trials capture only a few years, the two estimates, though divergent in raw magnitude, are mutually consistent once exposure duration is accounted for.
Does it work?
Not yet evaluated.
Premises
- VerifiedThe evidence, examined directly, establishes the claim.constitution →Statin randomized trials reduce major vascular events by about a fifth per 1 mmol/L reduction in LDL cholesterol
- VerifiedThe evidence, examined directly, establishes the claim.constitution →Mendelian randomization estimates roughly threefold greater cardiovascular risk reduction per mmol/L lower LDL than statin randomized trials
- UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →The cardiovascular risk reduction per unit of LDL lowering increases with longer duration of exposure
Where it is made
Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.
No source is recorded as making it.
Earlier ratings
- Jul 19, 2026
With the claim now stated as mutual consistency once duration of exposure is accounted for, rather than face-value equality of per-unit coefficients, the inference goes through cleanly. Its load-bearing premise is that per-unit benefit increases with duration of exposure, which turns the roughly threefold raw gap (linked claim) from an apparent contradiction into an expected consequence of comparing lifelong genetic exposure with a few years of trial treatment (linked claim). All three premises are well established, so the reconciliation stands; the earlier caveat, that this is consistency and not numerical equality, is now carried by the claim's wording itself rather than qualifying the inference.
- Jul 19, 2026
The inference goes through, but only under an explicit caveat: the estimates "agree" in the sense of being mutually consistent and convergent, not in the sense of matching per-unit coefficients. Its load-bearing premise is that per-unit benefit increases with duration of exposure (linked claim), which converts the roughly threefold raw gap (linked claim) from an apparent contradiction into an expected consequence of comparing lifelong genetic exposure with a few years of trial treatment (linked claim). All three premises are well established, so the reconciliation stands; what it does not establish is face-value numerical equality of the per-unit estimates.